Dr. Wei-Lin Tan's research lab at Kincaid University published early-phase results this week for a second gene-therapy candidate, a treatment distinct from the science that spun out into Kestrel Biologics five years ago.
Dr. Wei-Lin Tan’s research lab at Kincaid University published early-phase results this week for a second gene-therapy candidate, a treatment targeting a rare inherited metabolic disorder that is scientifically distinct from the flagship therapy her lab’s earlier work produced for Kestrel Biologics, the Foundry Row biotech firm that spun out of her research five years ago. The results, published in a peer-reviewed journal, showed the experimental treatment reduced a key disease marker in nine of twelve early trial participants.
“This is genuinely different science from what became Kestrel’s lead program,” Tan said. “It shares some of the same delivery technology, but the target and the patient population are completely different. I want to be careful that people don’t assume this is just Kestrel’s work under a different name.”
A second line of research, still inside the university
Unlike the earlier work that led to Kestrel Biologics’ founding, Tan said this program has remained inside her university lab rather than being spun out into a separate company, at least so far. She said the distinction matters because it reflects a deliberate choice by Kincaid to keep some early-stage research inside the university longer before deciding whether commercialization makes sense.
“Not every result needs to become a company,” Tan said. “Sometimes the right next step is a larger academic trial, and sometimes it’s licensing the finding to an existing company rather than building a new one from scratch. We’re still deciding which path this one takes.”
This is genuinely different science from what became Kestrel’s lead program. It shares some of the same delivery technology, but the target and the patient population are completely different.
Dr. Wei-Lin Tan, Kincaid University
Kincaid’s tech-transfer strategy in action
Kincaid President Dr. Howard Faircloth said the results are an early test of the university’s technology-transfer office, established in the wake of Kestrel’s success to help faculty researchers decide how and when to commercialize findings rather than simply publish and move on. “Kestrel was the proof of concept,” Faircloth said. “What we’re watching now is whether that same office can help produce a second success without just repeating what Dr. Tan’s lab already did once.”
Faircloth declined to say whether the university is actively pursuing a spinout around the new results, saying only that “conversations are happening” with the technology-transfer office and outside investors. He said the university remains committed to giving early-stage faculty research more runway before requiring a decision on commercialization, a lesson he said Kincaid drew directly from Tan’s earlier experience.
A cautious reaction from industry
Elena Marchetti, chief executive of Kestrel Biologics, said she has followed the new results with interest but cautioned against reading too much into an early-phase trial with just twelve participants. “Twelve patients and nine responders is a genuinely encouraging early signal,” Marchetti said. “It is not the same thing as a therapy that’s ready for the market, and I’d hate for people to conflate the two stages, because the distance between them is enormous.”
Marchetti said Kestrel has no formal involvement in the new research program and does not currently have a licensing arrangement tied to it, though she said the company would “obviously pay close attention” to how the university chooses to develop the science further. “We know better than almost anyone how far a result like this still has to travel,” she said.
Economic implications, if the trend continues
Dr. Samuel Iyer, a labor economist at Bellwater State University who studies the region’s tech-sector growth, said a second successful Kincaid-linked gene-therapy program, even one still years from commercialization, would reinforce a narrative he said is already shaping the region’s workforce planning. “One biotech spinout could be described as an outlier,” Iyer said. “A second research line showing this kind of early promise starts to look like a pattern, and patterns are what employers and workforce-training programs actually plan around.”
Iyer cautioned that any hiring impact remains speculative at this stage, since the research has not yet led to a company, let alone hiring plans. “I don’t want to get ahead of twelve patients in an early trial,” he said. “But if this becomes even a fraction of what Kestrel became, it’s another data point for the argument that Bellwater’s biotech cluster isn’t a one-company story.”
Tan said her lab plans to begin a larger follow-up trial within the next year, pending additional funding from a combination of federal grants and, potentially, private investment. She said several of her current graduate students have already asked to work specifically on the new program, a level of interest she said would have been unusual before Kestrel’s success made commercialization feel like a realistic career path within her lab.
“I used to have to convince people that staying in Bellwater to do this kind of work wasn’t a step down,” Tan said. “Now people are lining up to work on whatever comes after Kestrel, and I don’t take that for granted.”